Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.64 |
| ▸ | DRD3 | P35462 | 9/20 | 0.64 |
| ▸ | DRD4 | P21917 | 3/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446303 | 1.00 | DRD2 (0.64) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL17446277 | 1.00 | DRD2 (0.64) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL17446278 | 1.00 | DRD2 (0.64) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL17446304 | 1.00 | DRD2 (0.64) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL17446305 | 0.94 | DRD2 (0.57) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL2486274 | 0.85 | DRD2 (0.72) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL7899018 | 0.85 | DRD2 (0.72) | DRD2DRD3DRD4HTR1DMTNR1A | |
| Bromide SCHEMBL2482899 | 0.84 | DRD2 (0.70) | DRD2DRD3DRD4HTR1DMTNR1A | |
| SCHEMBL7454456 | 0.78 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL12072682 | 0.78 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SPRIASO LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SPRIASO LLC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9956201-B2 | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | SPRIASO LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956201-B2 | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms | SPRIASO LLC (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2016014242-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC (US) | 2016-01-28 | — | — | WO | disclosed |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SPRIASO LLC | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016887-A1 | Methods of treating a subject using bioreversible derivatives of hydroxy n-substituted-2-aminotetralins | SLC7A1, CYP2D6, SLC19A1 | DRD2 1496/4885DRD3 1430/4885DRD4 1516/4885 |
| US-20160015684-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N- SUBSTITUTED-2-AMINOTETRALINS, DOSAGE FORMS, AND RELATED METHODS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1602/4885DRD3 1564/4885DRD4 1742/4885 |
| US-20180177760-A1 | COMPOSITIONS COMPRISING BIOREVERSIBLE DERIVATIVES OF HYDROXY N-SUBSTITUTED-2-AMINOTETRALINS, AND RELATED DOSAGE FORMS | SLC7A1, CYP2D6, CYP3A7 | DRD2 1234/4885DRD3 1281/4885DRD4 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.